Click to close

Contact us

Please complete the required fields.

*Required Fields

Send

US Toll-free: 1-888-286-4003 International: 1-978-347-1143 contact@visresearch.com

Click to close

Request a Demo

Please complete the required fields.

*Required Fields

Request a Demo

US Toll-free: 1-888-286-4003 International: 1-978-347-1143 contact@visresearch.com

Click to close

Report Problem

Please complete the required fields.

*Required Fields

Send

US Toll-free: 1-888-286-4003 International: 1-978-347-1143 contact@visresearch.com

Login

Click to close

Please complete the required fields.

Forgot your password? Register

Tell us your email address and we'll send you instructions on how to reset your password.

Click to close

Resolution not supported

Click to close

Saving...

 0%

Samodzielny Publiczny Szpital kliniczny Nr 4 w Lublinie

Doktor Kazimierza Jaczewskiego 8, Lublin, Lubelskie
20-954
Poland
Website | ViS Profile

Center Profile Completeness

About
- Center
- Location
Infrastructure
- General
- Disease-Specific
Patients
- General
- Disease-Specific
Team
- Personnel
- Investigators
Expertise
- General
- Disease-Specific
Research
- Trials
- Publications
Network
- Disease-Specific

Trials in this area

- Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections (Calixa Therapeutics, Inc.; NCT00921024; Year 2009)

- A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma (Hoffmann-La Roche; NCT00943826; Year 2009)

- Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF) (Cytokinetics, Amgen; NCT01300013; Year 2011)

- A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Alone and in Combination for the Treatment of Overactive Bladder (Astellas Pharma Europe BV; NCT01340027; Year 2011)

- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis (Hoffmann-La Roche; NCT01412333; Year 2011)

Investigators in this area

  • Andrzej Nowakowski
  • Artur Jakimiuk
  • Maria Majdan
  • Andrzej Wysokinski
  • Zbigniew Stelmasiak
  • Jan Oleszczuk
  • Krzysztof Celiński
  • Jaroslaw Wójcik
  • Janusz Milanowski
  • Maria Slomka
  • Nowakowski Andrezej
  • Krzysztof Bar
  • Jan Blache
  • Andrzej Ksiazek
  • Tomasz Rechberger
  • Slawomir Rudzki

Diseases in this area

  • Rheumatoid Arthritis
  • Hematologic Cancer
  • Non-Small Cell Lung (NSCLC)
  • Gout
  • Multiple Sclerosis
  • CNS Demyelinating Disorder
  • Peripheral Diabetic Neuropathy
  • Sarcoidosis
  • Osteoarthritis
  • Inflammatory Polyarthropathies
  • Liver Cirrhosis
  • Lung Cancer
  • Overactive Bladder
  • Ischemic Heart Disease
  • Systemic Connective Tissue Disorder
  • Diseases of Bladder and Urethera
  • Diabetes
  • Prostate Cancer
  • Heart Failure
  • Diabetic Neuropathy
  • Systemic Lupus Erythematosus (SLE)
  • Viral Hepatitis B
  • Renal Failure
  • Arrhythmia
  • HPV
  • Sinusitis
  • Peripheral Vascular Disease
  • Congenital Cardiovascular Disorder
  • Inflammatory Bowel Disease
  • Ulcerative colitis
  • Bacterial Infection
  • Arterial Disorder, excl. Heart and CNS
  • Anemia
  • Herpes
  • Sleep Apnea
  • Bladder Cancer
  • Cervical Cancer
  • Urinary Tract Cancer
  • Crohns Disease
  • Low Back Pain
  • Bone Disorder, excl. Osteoporosis
  • Renal Disease
  • Dorsopathies
  • Movement Disorder
  • COPD
  • Upper Respiratory Tract Infection
  • Brain Cancer
  • Gastroesophageal Reflux Disease (GERD)
  • Seizure Disorder
  • Functional Colonic Disease

Click to close
Click to close

Add to network